Pradžia › Atopinis dermatitas (egzema) › Indianas
Atopinis dermatitas (egzema) klinikiniai tyrimai Indianas
9 tyrimai dėl Atopinis dermatitas (egzema) ieško dalyvių vietose Indianas.
Miestai Indianas
Oficialus tyrimo tekstas (anglų kalba)
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- Clinical Site 106, Plainfield
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-29 · NCT07453602Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Clarksville
- Enveda Investigative Site, New Albany
- Enveda Investigative Site, West Lafayette
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Renkami dalyviai3 fazė
Amžius nuo 2 iki 11 · Visoms lytims · Atnaujinta 2026-09-25 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- DS Research of Southern Indiana,LLC, Clarksville
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-08-28 · NCT07599813A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Indianapolis
- Enveda Investigative Site, Plainfield
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-06 · NCT07643766A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Dawes Fretzin /ID# 265097, Indianapolis
Renkami dalyviai3 fazė
Amžius nuo 2 iki 11 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Options Research Group /ID# 264564, West Lafayette
Renkami dalyviai3 fazė
Amžius nuo 18 iki 63 · Visoms lytims · Atnaujinta 2026-07-06 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- Southern Indiana Clinical Trials, New Albany
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-04 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 8142, Indianapolis
- Galderma Investigational Site 7083, West Lafayette
Renkami dalyviaiStebimasis tyrimas
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-03-13 · NCT06988605Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.